Literature DB >> 33251565

What does it mean to develop an HIV vaccine by rational design?

Marc H V van Regenmortel1.   

Abstract

This review argues that the three popular concepts of design, rationality and reductionism, which guided vaccine research for many years, actually contributed to the inability of vaccinologists to develop an effective HIV vaccine. The strong goal-directed intentionality inherent in the concept of design together with excessive confidence in the power of rational thinking convinced investigators that the accumulated structural knowledge on HIV epitopes, derived from crystallographic studies of complexes of neutralizing antibodies bound to HIV Env epitopes, would allow them to rationally design complementary immunogens capable of inducing anti-HIV protective antibodies. This strategy failed because it was not appreciated that the structures observed in epitope-paratope crystallographic complexes result from mutually induced fit between the two partners and do not represent structures present in the free disordered molecules before they had interacted. In addition, reductionist thinking led investigators to accept that biology could be reduced to chemistry, and this made them neglect the fundamental difference between chemical antigenicity and biological immunogenicity. As a result, they did not investigate which inherent constituents of immune systems controlled the induction of protective antibodies and focused instead only on the steric complementarity that exists between bound epitopes and paratopes.

Entities:  

Year:  2020        PMID: 33251565     DOI: 10.1007/s00705-020-04884-0

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  32 in total

Review 1.  Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS.

Authors:  M R Hilleman
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

Review 2.  The rational design of biological complexity: a deceptive metaphor.

Authors:  Marc H V Van Regenmortel
Journal:  Proteomics       Date:  2007-03       Impact factor: 3.984

3.  Too complex to comprehend?

Authors:  Frank Gannon
Journal:  EMBO Rep       Date:  2007-08       Impact factor: 8.807

Review 4.  Intrinsic and extrinsic factors in protein antigenic structure.

Authors:  J A Berzofsky
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

Review 5.  Truth in science and in molecular recognition, post-truth in human affairs.

Authors:  Marc H V Van Regenmortel
Journal:  J Mol Recognit       Date:  2019-12-03       Impact factor: 2.137

6.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Authors:  Erin M Scherer; Daniel P Leaman; Michael B Zwick; Andrew J McMichael; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 7.  Order without design.

Authors:  Alexei Kurakin
Journal:  Theor Biol Med Model       Date:  2010-04-14       Impact factor: 2.432

Review 8.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Basic research in HIV vaccinology is hampered by reductionist thinking.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2012-07-09       Impact factor: 7.561

10.  Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

View more
  1 in total

1.  Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?

Authors:  Karen Manoutcharian; Jesus Guzman Valle; Goar Gevorkian
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-04-28       Impact factor: 4.291

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.